- Headquarters
- Heidelberg
- Employees
- 51–200
- Founded
- 2000
- Business Model
- B2B
- Website
- affimed.com
- Total Funding
- $101.0M
- Last Round
- $19.4M Series ESep 2014
- Rounds
- 5
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Affimed is a clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, developing innate cell engager (ICE) therapies for oncology. Its proprietary tetravalent bispecific antibody platform redirects NK cells and macrophages to tumor cells by binding CD16A on innate immune effector cells and tumor-associated antigens such as EGFR (AFM24) and CD123 (AFM28). Affimed trades on NASDAQ under the ticker AFMD.
Summary
Affimed is a Biotech company based in Heidelberg, Germany, founded in 2000. It has raised $101.0M in total across 5 rounds, most recently a $19.4M Series E round in Sep 2014. Investors include OrbiMed, Aeris Capital and Public Investment Fund.
Funding & Exit History
Sep 2014
Sign up to see all 6 events
Funding: Series A through Series E. Amounts, valuations, and investors where available.
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/affimed"><img src="https://indexed.vc/api/badge/company/affimed" alt="Affimed on Indexed.vc" width="260" height="76" /></a>